MigVax Overview
MigVax was established as a special purpose vehicle by Migal, which granted MigVax an exclusive, worldwide license to make, use, and practice the vaccine technology for the development, manufacture, and commercialization of vaccines for viruses in humans, starting with COVID-19. The COVID-19 vaccine project was initiated upon the interdisciplinary research team’s successful development of a vaccine against infectious bronchitis virus (IBV), an avian (poultry) coronavirus with high similarity to today’s human COVID-19 that uses the same infection mechanism. Given the similarity, and following the required genetic adjustments, the same vaccination concepts should apply. MigVax’s sub-unit vaccine approach utilizes a chimeric protein that presents the viral proteins to the immune system via the oropharynx. This method, based on the IBV vaccine, generates three types of immunological response: mucosal immunity (IgA), blood-based immunity (IgG), and cell-mediated immunity.
Cumulative Funding Raised Over Time ($)
$16.0MApr 2020
$16.5MAug 2022
$17.0MDec 2021
Latest News
growth-positive
Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax have signed a development agreement to utilize Catalents Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine. The partnership aims to simplify the transportation, storage, and administration of the oral COVID-19 vaccine, making it easier and cost-effective for mass-vaccination programs. Catalent will conduct a feasibility study to formulate MigVax-101 into a Zydis Bio ODT dose form. The Zydis technology offers advantages such as improved patient compliance and convenience. The collaboration between Catalent and MigVax is a major step forward in global distribution and addressing the challenges of cold chain storage and transport. Catalents Zydis facility in Swindon, U.K., will carry out the work.
Partners
growth-positive
MigVax Appoints Ran Amir As Its New CEO
MigVax Ltd. has appointed Ran Amir as its new CEO as the company prepares to scale up its business and advance its oral subunit vaccine against COVID-19. The company has achieved proof-of-concept and received a prestigious grant for its groundbreaking vaccine. Ran Amir, with experience in scaling up technology-focused startups, is expected to accelerate MigVaxs momentum. The companys next-generation sub-unit oral vaccine aims to meet market needs for affordable and easier-to-administer booster solutions. MigVax is currently seeking financing for its Phase 1 & 2 clinical trials. The companys vaccine has demonstrated positive results in preclinical tests. MigVax is an affiliate of The Migal Galilee Research Institute and received investment from OurCrowd.
Management ChangesExpand
growth-positive
https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020
MigVax, an affiliate of MIGAL Galilee Research Institute, has received a $4.3 million grant from the Coalition of Epidemic Preparedness Innovations (CEPI) to develop its COVID-19 oral subunit vaccine tablet. The grant is part of a $200 million program to advance the development of vaccines that provide broad protection against COVID-19 variants or future coronaviruses. MigVax plans to use the grant to bring its vaccine to market faster and explore its potential use against other coronaviruses. The vaccine, called MigVax-101, is an oral subunit vaccine that presents the coronavirus antigen to the immune system without introducing pathogen particles. The grant recipients are required to commit to achieving equitable access to the vaccine outputs. CEPI is a partnership of public, private, philanthropic, and civil organizations focused on developing vaccines against future pandemics.
Investment
MigVax's Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster
growth-positive
After coronavirus vaccine success, is Israel's MigVax still needed? - Sponsored Content The Times of Israel
Israeli medical entrepreneurs emphasize the need for additional vaccine and treatment options to end the COVID-19 pandemic. MigVax, an Israeli company, is developing an oral vaccine for COVID-19 that could be available next year. The vaccine offers the advantage of being simple to distribute and use. SaNOtize, a Vancouver-based startup, has developed a nasal spray that kills COVID-19 and other infections. Clinical trials are underway to confirm the safety of the spray. The spray could be on the market as a preventative measure in mid-2021. The pandemic has also highlighted the need for breakthroughs and new methods to prevent or treat other viruses and improve the healthcare system.
CustomersPartners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $21.3M |
| Last funding | $500K |
| Stage | A |
| Rounds | 4 |
| Investors | 2 |
Team Members
4
Employees: 1-10
Web & Social Links
| Website | www.migvax.com/ |
| Careers | Careers page |
Locations
Tarshish Street 5, Kiryat Shmona, Israel
Photos & Videos
1 item(s)
MigVax Business
Business models
B2B
Product stage
R&D
Employees
1-10
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesLife SciencesPharmaceuticalsCore Technology
BiologicalsMoleculesTags (5)
immunologypharmaceuticalsdrug-developmentoral-drugsvaccinesMigVax Financials
$21.3M
Total funding
Undisclosed
Capital raised
$500K
Last funding
A
Funding stage
4
Total rounds
2
Investors
Cumulative Funding Raised Over Time ($)
$16.0MApr 2020
$16.5MAug 2022
$17.0MDec 2021
Private Equity Funding
Convertible Debt
Aug 2022
$500K
OurCrowd
Convertible Debt
Dec 2021
$500K
A Round
Apr 2020
$16M
OurCrowd (Lead)
,
Happiness Capital
Non-Equity Funding
GrantEvent
Nov 2021
$4.3M
The Coalition of Epidemic Preparedness Innovations (CEPI)
MigVax Lifecycle
Cumulative Funding Raised Over Time
$16.0MApr 2020
$16.5MAug 2022
$17.0MDec 2021
All Events
Convertible Debt
Aug 2022
$500K
OurCrowd
Convertible Debt
Dec 2021
$500K
A Round
Apr 2020
$16M
OurCrowd (Lead)
,
Happiness Capital
GrantEvent
Nov 2021
$4.3M
The Coalition of Epidemic Preparedness Innovations (CEPI)
MigVax News
12 articles
growth-positive
Catalent and MigVax Sign Agreement to Develop an Orally Disintegrating Freeze-Dried Tablet Vaccine Against COVID-19
Catalent and MigVax have signed a development agreement to utilize Catalents Zydis Bio orally disintegrating tablet (ODT) technology for delivering the MigVax-101 vaccine. The partnership aims to simplify the transportation, storage, and administration of the oral COVID-19 vaccine, making it easier and cost-effective for mass-vaccination programs. Catalent will conduct a feasibility study to formulate MigVax-101 into a Zydis Bio ODT dose form. The Zydis technology offers advantages such as improved patient compliance and convenience. The collaboration between Catalent and MigVax is a major step forward in global distribution and addressing the challenges of cold chain storage and transport. Catalents Zydis facility in Swindon, U.K., will carry out the work.
Partners
growth-positive
MigVax Appoints Ran Amir As Its New CEO
MigVax Ltd. has appointed Ran Amir as its new CEO as the company prepares to scale up its business and advance its oral subunit vaccine against COVID-19. The company has achieved proof-of-concept and received a prestigious grant for its groundbreaking vaccine. Ran Amir, with experience in scaling up technology-focused startups, is expected to accelerate MigVaxs momentum. The companys next-generation sub-unit oral vaccine aims to meet market needs for affordable and easier-to-administer booster solutions. MigVax is currently seeking financing for its Phase 1 & 2 clinical trials. The companys vaccine has demonstrated positive results in preclinical tests. MigVax is an affiliate of The Migal Galilee Research Institute and received investment from OurCrowd.
Management ChangesExpand
growth-positive
https://www.jpost.com/health-and-wellness/coronavirus/israels-migvax-oral-vaccine-scores-34-m-to-fast-track-development-684020
MigVax, an affiliate of MIGAL Galilee Research Institute, has received a $4.3 million grant from the Coalition of Epidemic Preparedness Innovations (CEPI) to develop its COVID-19 oral subunit vaccine tablet. The grant is part of a $200 million program to advance the development of vaccines that provide broad protection against COVID-19 variants or future coronaviruses. MigVax plans to use the grant to bring its vaccine to market faster and explore its potential use against other coronaviruses. The vaccine, called MigVax-101, is an oral subunit vaccine that presents the coronavirus antigen to the immune system without introducing pathogen particles. The grant recipients are required to commit to achieving equitable access to the vaccine outputs. CEPI is a partnership of public, private, philanthropic, and civil organizations focused on developing vaccines against future pandemics.
Investment
MigVax's Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster
growth-positive
After coronavirus vaccine success, is Israel's MigVax still needed? - Sponsored Content The Times of Israel
Israeli medical entrepreneurs emphasize the need for additional vaccine and treatment options to end the COVID-19 pandemic. MigVax, an Israeli company, is developing an oral vaccine for COVID-19 that could be available next year. The vaccine offers the advantage of being simple to distribute and use. SaNOtize, a Vancouver-based startup, has developed a nasal spray that kills COVID-19 and other infections. Clinical trials are underway to confirm the safety of the spray. The spray could be on the market as a preventative measure in mid-2021. The pandemic has also highlighted the need for breakthroughs and new methods to prevent or treat other viruses and improve the healthcare system.
CustomersPartners
growth-positive
Ex-Teva CFO Eyal Desheh joins Israeli Covid-19 vaccine co
Israeli company MigVax has appointed Eyal Desheh as chairman of its board of directors. MigVax is developing an oral vaccine against Covid-19 based on research from the Migal Galilee Research Institute. Deshehs experience in the pharmaceutical industry is expected to assist MigVax in their vaccine development efforts. The company aims to turn the promising technology into an effective vaccine and build an advanced platform for further vaccine development.
PartnersExpand
growth-positive
Israeli Covid-19 vaccine developer MigVax raises $12m
Israeli Covid-19 vaccine developer MigVax Corp., an affiliate of the Migal Galilee Research Institute, has raised $12 million in funding led by OurCrowd. MigVax aims to develop a new oral subunit human vaccine against Covid-19 using methods learned from a previous vaccine developed by the institute. The vaccine has shown high safety and efficiency in animal models, and the company plans to have the material ready for clinical trials within a few months.
Investment
growth-positive
MigVax raises $12M for its COVID-19 vaccine efforts
Israeli startup MigVax receives $12 million investment from OurCrowd to accelerate the development of an oral COVID-19 vaccine. MigVaxs approach, which uses bacterial fermentation to produce the vaccine, offers advantages in manufacturing and cost. The company aims to have the material ready for clinical trials within a few months. OurCrowd CEO Jon Medved expresses gratitude for the opportunity to support the important effort of developing a COVID-19 vaccine. The funding reflects the growing interest and investment in startups working on COVID-19 vaccines.
InvestmentPartners
growth-positive
PRESS RELEASE: OurCrowd Leads $12M Investment in Israeli Covid-19 Vaccine Company MigVax - OurCrowd Blog
OurCrowd, the worlds largest crowdfunding venture investment platform, is leading a $12 million investment in MigVax Corp., an Israeli company developing a novel COVID-19 vaccine. MigVax is an affiliate of The Migal Galilee Research Institute and is using methods learned from a previous vaccine to develop a new oral subunit human vaccine against COVID-19. The investment will accelerate the path to clinical trials and bring the vaccine to market. OurCrowd CEO Jon Medved expressed gratitude for the opportunity to support this important effort. The vaccine has shown high safety and efficiency in animal models, and the approach taken by MigVax is believed to be safer with a higher likelihood of achieving a meaningful immune response.
Investment
growth-positive
https://www.jpost.com/HEALTH-SCIENCE/Israeli-scientists-In-three-weeks-we-will-have-coronavirus-vaccine-619101
Israeli scientists at MIGAL are close to developing the first vaccine against the novel coronavirus. The vaccine could be ready within a few weeks and available in 90 days. MIGAL has been working on a vaccine for infectious bronchitis virus (IBV), and they found that the poultry coronavirus has high genetic similarity to the human one. They are adjusting their system to the new sequence and hope to have the vaccine in a few weeks. MIGAL is in discussions with potential partners to accelerate the in-human trials phase and expedite final-product development and regulatory activities.
InvestmentPartnersCustomers
growth-positive
Israeli R&D Team Claim To Be Near COVID-19 Vaccine
Israeli research team MIGAL has discovered a potential COVID-19 vaccine candidate as a by-product of an avian vaccine they were developing. They hope to start producing and testing the vaccine by May.
InvestmentExpand
growth-positive
Israeli Scientists Work To Test Adapted New Avian Virus Vaccine Against Human Coronavirus
Scientists at the Migal Research Institute in Israel have developed a vaccine for a deadly virus affecting poultry that could be adapted for human use against the novel coronavirus. The vaccine has been proven effective in pre-clinical veterinary trials. The scientists identified a possible COVID-19 vaccine candidate as a by-product of the avian vaccine and have made the required genetic adjustments to adapt the vaccine to COVID-19. The institute aims to produce the vaccine over the next two months and achieve safety approval in 90 days.
InvestmentPartners
MigVax Team
Employee Info
| Employees (range) | 1-10 |
| Exact count | 9 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 8 classification IDs that could be used for matching.
MigVax Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 90/100 |
| Missing | markets, not claimed |
| BI Verification | Yanina Wainscheinker |
| Registrar ID | 516178084 |
| Crunchbase | migvax |
| Phone | +97246953511 |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-22T00:00:00.000Z |
| Created | 2020-04-22T00:00:00.000Z |